Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Evogene (EVGN) over the last 15 years, with Q3 2025 value amounting to $77000.0.

  • Evogene's Current Deferred Revenue fell 8962.26% to $77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $77000.0, marking a year-over-year decrease of 8962.26%. This contributed to the annual value of $360000.0 for FY2024, which is 839.69% down from last year.
  • According to the latest figures from Q3 2025, Evogene's Current Deferred Revenue is $77000.0, which was down 8962.26% from $99000.0 recorded in Q2 2025.
  • In the past 5 years, Evogene's Current Deferred Revenue registered a high of $742000.0 during Q3 2024, and its lowest value of $16000.0 during Q2 2022.
  • Moreover, its 5-year median value for Current Deferred Revenue was $192000.0 (2021), whereas its average is $263611.1.
  • Per our database at Business Quant, Evogene's Current Deferred Revenue plummeted by 9534.05% in 2021 and then skyrocketed by 235000.0% in 2023.
  • Quarter analysis of 5 years shows Evogene's Current Deferred Revenue stood at $175000.0 in 2021, then plummeted by 87.43% to $22000.0 in 2022, then soared by 1686.36% to $393000.0 in 2023, then dropped by 8.4% to $360000.0 in 2024, then plummeted by 78.61% to $77000.0 in 2025.
  • Its Current Deferred Revenue stands at $77000.0 for Q3 2025, versus $99000.0 for Q2 2025 and $209000.0 for Q1 2025.